Cardiometabolic Effectiveness with GLP-1 Receptor Therapy

Discover the impact of GLP-1 receptor therapy on cardiometabolic wellness and disease management in the body.

Abstract

In this educational post, I, Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, walk you through a modern, evidence-based approach to diabetes care that prioritizes cardiovascular and renal protection alongside glucose control. I explain why the FDA’s mandate for cardiovascular outcomes trials has reshaped our treatment choices and how specific therapies, including SGLT2 inhibitors and GLP-1 receptor agonists, reduce major adverse cardiovascular events, heart failure, and the progression of chronic kidney disease. I detail our multidisciplinary model at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, where I integrate chiropractic, functional medicine, rehabilitation, and personal injury services under the medical oversight of Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), our Medical Director and Collaborative Physician with over 40 years of internal medicine experience. I also discuss the common clinical challenge of over-basalization, why GLP-1 receptor agonists often outperform adding prandial insulin, and how chiropractic care fits into a comprehensive cardiometabolic plan. Throughout, I share clinical observations from my practice and highlight landmark trials and guidelines that inform our protocols.

Reframing Diabetes Care: A Cardiometabolic Risk-Reduction Paradigm

Over the years, I have watched diabetes care evolve from a narrow focus on glucose to a comprehensive cardiometabolic strategy. Today, our shared mission across internal medicine, cardiology, endocrinology, and nephrology is to reduce global cardiometabolic risk.

• People with diabetes have a markedly higher risk of myocardial infarction, stroke, peripheral artery disease, and cardiovascular death; normalizing glucose alone does not normalize cardiovascular risk (American Diabetes Association [ADA], 2023).
• The convergence of recommendations from ADA, the American College of Cardiology/American Heart Association (ACC/AHA), and Kidney Disease: Improving Global Outcomes (KDIGO) underscores a shift toward therapies that directly reduce cardiovascular and renal events (ADA, 2023; ACC/AHA, 2022; KDIGO, 2022).

Evidence from large cardiovascular outcomes trials shows that certain SGLT2 inhibitors and GLP-1 receptor agonists do more than avoid harm—they actively protect the heart and kidneys by lowering MACE, heart failure hospitalizations, and CKD progression (Zinman et al., 2015; Marso et al., 2016; McMurray et al., 2019; Anker et al., 2021; Heerspink et al., 2020; Herrington et al., 2023).

Why this matters in practice:

• We now select therapies not only for A1C reduction but for their proven ability to prevent complications that most often lead to disability and death.
• We routinely co-manage blood pressure, lipids, inflammation, weight, sleep, and smoking cessation—because cardiometabolic risk is multifactorial.

How FDA Cardiovascular Outcomes Trials Changed Diabetes Treatment

Around 2008–2009, the FDA required that new glucose-lowering agents undergo long-term cardiovascular outcomes trials (CVOTs) to ensure they did not increase cardiovascular risk. This changed everything.

• CVOTs revealed that some agents reduce cardiovascular and renal events beyond glycemic effects.
• Landmark trials include:

• • EMPA-REG OUTCOME: Empagliflozin reduced cardiovascular death, all-cause mortality, and heart failure hospitalization in type 2 diabetes with established CVD (Zinman et al., 2015).
  • LEADER: Liraglutide reduced MACE in high-risk patients (Marso et al., 2016).
  • Additional trials such as DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DAPA-CKD expanded benefits to patients with and without diabetes, as well as those with chronic kidney disease (McMurray et al., 2019; Packer et al., 2020; Anker et al., 2021; Heerspink et al., 2020).

Physiologically, these benefits reflect hemodynamic shifts (natriuresis, reduced preload/afterload), renal tubular mechanisms (restored tubuloglomerular feedback), and anti-inflammatory/anti-atherosclerotic effects that extend far beyond A1C.

Clinical Algorithms Converge: When to Use SGLT2 Inhibitors and GLP-1 Receptor Agonists

Guidelines now prioritize agents with proven outcome benefits in patients with high cardiovascular or renal risk (ADA, 2023; ACC/AHA, 2022; KDIGO, 2022).

• For patients with ASCVD or high ASCVD risk:

• • Start a GLP-1 receptor agonist with demonstrated MACE reduction (e.g., liraglutide, semaglutide; LEADER; SUSTAIN-6).
  • Add an SGLT2 inhibitor for complementary heart failure and renal protection.

• For heart failure (HFrEF and HFpEF):

• • Prioritize SGLT2 inhibitors given consistent reduction in HF hospitalizations and composite endpoints (DAPA-HF; EMPEROR-Reduced; EMPEROR-Preserved).

• For chronic kidney disease:

• • Prefer SGLT2 inhibitors to slow CKD progression and reduce renal endpoints (DAPA-CKD; EMPA-KIDNEY).
  • Consider GLP-1 RAs with renal benefits to reduce albuminuria further and support weight and blood pressure control.

In many patients, using both classes offers a synergistic, multi-organ risk reduction strategy.

SGLT2 Inhibitors: How Kidney-Level Actions Protect the Heart and Kidneys

Blocking sodium-glucose cotransporter-2 at the proximal tubule reduces glucose and sodium reabsorption, triggering systemic benefits:

• Natriuresis and osmotic diuresis: Reduces intravascular volume, preload, and left ventricular filling pressures—key in heart failure stabilization.
• Lower systolic blood pressure: Typically by ~4–5 mmHg, reducing afterload and vascular stress.
• Restored tubuloglomerular feedback: Lowers intraglomerular pressure and hyperfiltration, protecting against CKD progression.
• Metabolic remodeling: Enhances myocardial energy efficiency (e.g., greater ketone utilization), reduces oxidative stress and fibrosis.
• Weight loss: Often a 2–3 kg reduction, counteracting weight-promoting therapies.

Clinical impact:

• HFrEF: Dapagliflozin reduced CV death or HF hospitalization by ~26% (DAPA-HF; McMurray et al., 2019).
• HFpEF: Empagliflozin reduced primary composite endpoints and HF hospitalizations (EMPEROR-Preserved; Anker et al., 2021).
• CKD: Dapagliflozin reduced renal endpoints and slowed eGFR decline, even in non-diabetic CKD (DAPA-CKD; Heerspink et al., 2020). EMPA-KIDNEY reinforced kidney protection across a broad CKD population (Herrington et al., 2023).

Why we use them even at lower eGFR:

• Glycemic effects wane as eGFR falls, but hemodynamic and tubular benefits persist, making them valuable for HF and CKD risk reduction.

GLP-1 Receptor Agonists: Vascular and Metabolic Protection Beyond A1C

GLP-1 RAs restore the blunted incretin axis in type 2 diabetes:

• Glucose-dependent insulin secretion and glucagon suppression: Improves postprandial and fasting glucose with low hypoglycemia risk when not combined with sulfonylureas or insulin.
• Slowed gastric emptying and central appetite suppression: Drives meaningful weight loss and improved satiety.
• Vascular effects: Anti-inflammatory and anti-atherosclerotic actions improve endothelial function and stabilize plaque; modest blood pressure reductions contribute to risk lowering.

Key trials and takeaways:

• LEADER (liraglutide): Reduced MACE in high-risk T2D (Marso et al., 2016).
• SUSTAIN-6 and PIONEER 6 (semaglutide): Confirmed cardiovascular benefits with injectable and oral formulations (Marso et al., 2016; Husain et al., 2019).
• REWIND (dulaglutide): Demonstrated benefits in a broader population, including many without established ASCVD, supporting primary prevention utility (Gerstein et al., 2019).
• FLOW (semaglutide): Early-stopped for kidney benefit signals; growing evidence supports renal protection (Perkovic et al., 2024).

Clinical selection:

• Semaglutide: Robust A1C and weight effects; available as a weekly injectable and oral options.
• Dulaglutide: Weekly; strong CVOT data across diverse risk profiles.
• Liraglutide: Daily; foundational CVOT evidence.
• Tirzepatide (GIP/GLP-1 dual agonist): Exceptional A1C and weight effects; cardiovascular outcome results are maturing and promising.

We always “start low, go slow” to mitigate GI effects and ensure long-term adherence.

Over-Basalization: When More Basal Insulin Isn’t Better

In my practice, I frequently meet patients whose A1C remains elevated despite increasing basal insulin doses. Over-basalization occurs when basal insulin exceeds the dose needed to control fasting glucose but fails to address postprandial spikes.

Signs of over-basalization:

• Basal dose >0.5 units/kg/day with diminishing returns.
• Fasting glucose near target but postprandial glucose consistently elevated (e.g., >180 mg/dL).
• A1C remains above goal despite good morning readings.
• A large bedtime-to-morning drop, suggesting overnight coverage is adequate while meals remain under-treated.

Why GLP-1 RAs often beat adding prandial insulin:

• GLP-1 RAs target postprandial hyperglycemia, reduce appetite, and lead to weight loss—addressing root drivers of insulin resistance.
• Prandial insulin lowers post-meal glucose but commonly adds weight and hypoglycemia risk, counterproductive in patients already struggling with obesity and cardiometabolic risk.

Case example from clinic:

• A 62-year-old man on metformin, an SGLT2 inhibitor, statin, ARB, and 65 units of degludec daily (≈0.65 U/kg) had A1C 8.2%, fasting 110–150 mg/dL, and postprandial 160–200 mg/dL. Adding a GLP-1 RA, while maintaining SGLT2 therapy and optimizing lifestyle, addressed postprandial peaks, reduced weight, and improved A1C with fewer hypoglycemic events.

---

The Silent Threat: Hyperhomocysteinemia and its Impact on Your Health- Video

---

Our Multidisciplinary Model: Medical Oversight Meets Integrative Chiropractic

At Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, our model blends medical and conservative care under one roof:

• Medical Direction and Collaborative Physician: Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine (NPI #1164426749; Texas MD License #J2933), serves as Medical Director and Collaborative Physician. With over 40 years in internal medicine, she oversees diagnostics, prescribing, safety monitoring, and coordination with subspecialists.
• Integrative Chiropractic and Functional Medicine: I integrate chiropractic medicine with family nurse practitioner training and functional medicine to address biomechanical integrity, autonomic balance, and inflammatory load—factors that strongly influence metabolic control and exercise capacity.
• Rehabilitation and Personal Injury Care: We address pain and movement barriers that impede adherence to physical activity, a cornerstone of cardiometabolic risk reduction.

Why this matters:

• Internal medicine oversight ensures safe integration of SGLT2 inhibitors and GLP-1 RAs with antihypertensives, diuretics, and statins, particularly in CKD and HF.
• Chiropractic and rehab improve mobility, reduce nociception, and facilitate graded exercise, which amplifies pharmacologic benefits.

You can explore more of my clinical commentary and cases on my website and professional profile:

• www.dralexjimenez.com
• www.linkedin.com/in/dralexjimenez/

Physiological Rationale: How Chiropractic Fits Cardiometabolic Care

Chronic pain, dysfunctional movement, and poor biomechanics increase sympathetic activity and inflammatory cytokines (e.g., IL-6, TNF-α), worsening insulin resistance and blood pressure control. Improving musculoskeletal function and autonomic balance supports cardiometabolic goals.

Key mechanisms and benefits:

• Autonomic regulation: By reducing nociceptive input and enhancing segmental mobility, chiropractic care can improve heart rate variability—a marker of vagal tone—and reduce sympathetic overdrive associated with hypertension and insulin resistance (Thayer & Lane, 2007).
• Respiratory mechanics: Restoring thoracic and rib motion improves ventilatory efficiency and oxygenation, enabling higher-intensity exercise that increases mitochondrial density and endothelial nitric oxide availability.
• Microvascular perfusion: Soft-tissue mobilization reduces fascial restriction and improves microcirculatory flow, facilitating substrate delivery and metabolite clearance during exercise.
• Gait economy and joint unloading: Optimizing alignment and lower-extremity mechanics empowers patients with neuropathy or PAD to adhere to walking programs that improve collateral circulation and endothelial function.

When combined with SGLT2-induced volume and pressure benefits and GLP-1 RA-driven weight loss and vascular anti-inflammatory effects, these biomechanical and autonomic improvements produce a synergistic reduction in cardiometabolic risk.

Practical Integration: How We Combine SGLT2 Inhibitors and GLP-1 RAs in Clinic

From a practical standpoint, we aim for simple, sustainable regimens:

• SGLT2 inhibitor dosing:

• • Morning dosing to minimize nocturia.
  • Emphasize hydration and hygiene to lower risk of genital mycotic infections; early topical antifungals often suffice.
  • Continue at lower eGFR for HF and renal protection even when A1C impact declines.

• GLP-1 RA initiation:

• • Start low, go slow; titrate over weeks to reduce GI side effects.
  • Provide nutritional coaching (protein prioritization, smaller meals, hydration) to support tolerability and lean mass preservation.

• Baseline therapies:

• • Extended-release metformin for GI tolerability.
  • ACE inhibitor or ARB for hypertension and albuminuria.
  • Statin therapy aligned with LDL targets and ASCVD risk.

• Monitoring:

• • Regular A1C, eGFR, urine albumin-to-creatinine ratio, lipids, blood pressure, and weight/body composition.
  • Watch for volume depletion (especially with diuretics), orthostasis, and GLP-1 RA GI effects; adjust pharmacotherapy promptly.

In my experience, these measures increase adherence and outcomes while maintaining a favorable safety profile.

Case Walkthrough: Integrative Strategy After MI in Long-Standing Type 2 Diabetes

Patient profile:

• 72-year-old woman with 15+ years of type 2 diabetes, recent MI with stents, A1C 8.1%, eGFR 55 mL/min/1.73 m², on metformin 2,000 mg/day and sitagliptin 50 mg/day.

Goals:

• Reduce MACE and heart failure risk post-MI.
• Improve glycemic control and preserve kidney function.
• Restore movement and reduce barriers to activity due to pain.

Plan and rationale:

• Add an SGLT2 inhibitor (empagliflozin or dapagliflozin): For HF prevention and renal protection. Morning dosing with hydration guidance reduces nocturia and supports daytime activity.
• Add a GLP-1 RA (liraglutide or semaglutide): For ASCVD risk reduction and weight control. Slow titration to enhance GI tolerability.
• Optimize metformin to extended-release for once-daily morning dosing.
• Medical oversight: Monitor blood pressure, eGFR, electrolytes, and lipids; adjust ACEi/ARB and statin intensity per guideline targets.
• Chiropractic and rehab: Address thoracic mobility and scapular mechanics for respiratory efficiency; lumbo-pelvic stability for gait endurance; implement graded walking, progressing to resistance and intervals as tolerated.
• Nutrition, sleep, and stress: Anti-inflammatory, low-glycemic nutrition with adequate protein; sleep hygiene and stress resilience to improve insulin sensitivity and blood pressure.

Expected outcomes:

• ~1% A1C reduction with SGLT2, more with GLP-1 RA; reduced HF hospitalization risk; slowed CKD progression; improved functional capacity and adherence to activity.

Stepwise Protocol: Building a Comprehensive Cardiometabolic Pathway

• Risk stratification

• • Identify ASCVD, HF phenotype (HFrEF vs HFpEF), CKD stage, and lifestyle barriers.
  • Use ADA, ACC/AHA, and KDIGO algorithms to prioritize SGLT2 and GLP-1 RA for high-risk profiles.

• Pharmacologic foundation

• • SGLT2 inhibitor for HF and CKD protection; morning dosing with hydration and hygiene education.
  • GLP-1 RA for ASCVD risk reduction and weight loss; titrate to balance efficacy and tolerability.
  • Optimize metformin, ACEi/ARB for albuminuria/hypertension, and statin intensity for LDL targets.

• Integrative chiropractic and rehabilitation

• • Correct postural and movement dysfunction to reduce sympathetic drive and pain.
  • Implement graded aerobic/resistance training; monitor volume status and orthostatic symptoms, especially when starting SGLT2 inhibitors.

• Functional medicine

• • Nutrition tailored to glycemic control and inflammation reduction; ensure micronutrient adequacy.
  • Sleep optimization and stress reduction to improve autonomic balance and insulin sensitivity.

• Monitoring and safety

• • Periodic checks of A1C, eGFR, urine albumin, blood pressure, lipids, and body composition.
  • Watch for SGLT2-related genital infections/volume depletion and GLP-1 RA GI effects; adjust promptly.

• Patient education and shared decision-making.

• • Clear guidance on hydration, hygiene, medication timing, and activity progression.
  • Align with patient preferences, insurance coverage, and cultural context.

Why This Works: Connecting Mechanisms to Measurable Outcomes

• SGLT2 inhibitors: Lower intraglomerular pressure, reduce interstitial and intravascular volume, and improve ventricular loading conditions—directly affecting heart failure and CKD outcomes.
• GLP-1 receptor agonists: Decrease atherothrombotic risk through weight loss, blood pressure reductions, improved lipids, and anti-inflammatory, endothelial benefits—translating into fewer MACE.
• Chiropractic and rehab: Build the physiological foundation for sustained physical activity, improved autonomic tone, and lower pain-driven sympathetic load, amplifying pharmacologic benefits.
• Internal medicine oversight: Ensures safe coordination of therapies and timely titration based on objective monitoring.

In my practice, when pain is controlled and movement quality improves, patients achieve more consistent reductions in blood pressure, A1C, and central adiposity. Pharmacology sets the trajectory; integrative care powers the journey.

References

• American Diabetes Association. (2023). Standards of Medical Care in Diabetes—2023. Diabetes Care
• American College of Cardiology/American Heart Association. (2022). 2022 Guideline for the Management of Heart Failure. Circulation
• (2022). KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD
• Zinman, B., et al. (2015). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine
• Marso, S. P., et al. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine
• Wiviott, S. D., et al. (2019). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (DECLARE–TIMI 58). New England Journal of Medicine
• Neal, B., et al. (2017). Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS). New England Journal of Medicine
• McMurray, J. J. V., et al. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF). New England Journal of Medicine
• Packer, M., et al. (2020). Empagliflozin in Heart Failure with a Reduced Ejection Fraction (EMPEROR-Reduced). New England Journal of Medicine
• Anker, S. D., et al. (2021). Empagliflozin in Heart Failure with a Preserved Ejection Fraction (EMPEROR-Preserved). New England Journal of Medicine
• Heerspink, H. J. L., et al. (2020). Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). New England Journal of Medicine
• Herrington, W. G., et al. (2023). Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY). New England Journal of Medicine
• Husain, M., et al. (2019). Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6). New England Journal of Medicine
• Gerstein, H. C., et al. (2019). Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND). The Lancet
• Perkovic, V., Tuttle, K. R., Rossing, P., & Poggio, E. D. (2024). Semaglutide for kidney protection in type 2 diabetes. New England Journal of Medicine
• Thayer, J. F., & Lane, R. D. (2007). The role of vagal function in emotion regulation and health. Biological Psychology

SEO tags: cardiometabolic risk, diabetes cardiovascular outcomes, SGLT2 inhibitors heart failure, GLP-1 receptor agonists MACE reduction, chronic kidney disease nephroprotection, integrative chiropractic care, internal medicine collaborative clinic, empagliflozin Jardiance outcomes, dapagliflozin Farxiga DAPA-HF, liraglutide Victoza LEADER, semaglutide SUSTAIN-6 PIONEER-6, ADA ACC AHA KDIGO guidelines, over-basalization, prandial insulin alternative, El Paso Injury Medical Clinic, Dr Alex Jimenez DC APRN FNP-BC, Dr Maria Guadalupe Cardenas MD, functional medicine rehabilitation, personal injury integrative care, HFpEF HFrEF management, CKD albuminuria reduction, primary prevention REWIND, FLOW kidney protection